Close Menu

NEW YORK (360Dx) – T2 Biosystems is counting on the publication last week of a pivotal clinical trial to educate clinicians and drive adoption of its direct-from-blood instrument and tests.

The recent publication of the pivotal clinical study for its T2Bacteria panel in the Annals of Internal Medicine is an important milestone for T2 Biosystems, Tom Lowery, the firm's chief scientific officer, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.